▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3334 by analyst upside · 2026-11-14
BRKR
Bruker Corporation
Healthcare · Market Cap $9B · P/E 0x
ANALYST PRICE TARGET
+10.4%
implied upside to consensus target
Current Price $61.59
Consensus Target $68.0
Bull Target $85.0
Bear Target $55.0
Analysts Covering 12
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
5
Hold
6
Sell
0
52-Week Low $32.37
52-Week High $68.98
YTD Return +28.4%
FUNDAMENTALS
Market Cap $9B
P/E Ratio (TTM) N/A
Forward P/E 25.1x
EPS (TTM) $-1.10
PEG Ratio 1.52
Dividend Yield 0.33%
Revenue (TTM) $3.5B
Profit Margin -3.5%
52-WEEK RANGE
52-Week Low $32.37
52-Week High $68.98
Current Price $61.59
Bear Target $55.0
Bull Target $85.0
● Now $61.59 ● Target $68.0
TRADING DATA
Avg Volume 2.3M
YTD Return +28.4%
Analyst Count 12
Consensus Buy
Upside to Target +10.4%
Last Updated 2026-11-14

ANALYST SUMMARY

Bruker Corporation (BRKR) is currently trading at $61.59 with a Wall Street consensus price target of $68.0, implying potential upside of 10.4% over the next 12 months. 12 analysts currently cover BRKR, with a consensus rating of Buy - 50% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $85.0, while the most cautious has a target of $55.0.

BRKR operates in the Healthcare sector with a market capitalisation of $9B. The stock is up 28.4% year-to-date and is currently trading near the upper end of its 52-week range of $32.37 – $68.98.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

UHS +1.4%
Universal Health Services, Inc.
$11B · P/E 8.1x · Hold
GMED +29.5%
Globus Medical, Inc.
$10B · P/E 17.8x · Buy
HSIC +12.0%
Henry Schein, Inc.
$10B · P/E 23.6x · Buy
QGEN -0.2%
Qiagen N.V.
$10B · P/E 27.1x · Hold
FMS -0.2%
Fresenius Medical Care AG
$11B · P/E 12.7x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for BRKR, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citigroup - Reiterated
Neutral → Neutral 2026-11-05 Building track record
Leerink Partners - Reiterated
Outperform → Outperform 2026-11-05 29% win rate (7 calls)
JP Morgan ↓ Downgrade
Overweight → Neutral 2026-10-14 43% win rate (7 calls)
TD Cowen - Reiterated
Hold → Hold 2026-10-13 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-10-07 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-10-01 62% win rate (8 calls)
Leerink Partners - Reiterated
Outperform → Outperform 2026-09-29 29% win rate (7 calls)
UBS - Reiterated
Neutral → Neutral 2026-09-09 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
47
out of 100
Coverage depth
20/30
Consensus clarity
20/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →